| abstract |
The present invention provides parameters and conditions for the preparation of stable pharmaceutical compositions containing N- {4- (2,2-dimethylpropionyl) - (5R) -5 - [(2-ethylaminoethanesulfonylamino) methyl] -5-phenyl-4,5-dihydro - [1,3,4] thiadiazol-2-yl} -2,2-dimethylpropionamide, which minimize the undesired chiral transition of the indicated compound to the less active S-enantiomeric form. |